Keyword: Shire

Takeda to sell nearly new Shire plant with 200 employees

Friday, January 31, 2020

Takeda says will sell a $400 million biologics plant in Ireland that it picked up in its buyout of Shire but says it does not need.

Shire surprises Takeda with €398M tax bill on AbbVie breakup fee

by Angus Liu

Monday, January 13, 2020

The additional tax charge is related to the $1.64 billion breakup fee AbbVie paid Shire in its nixed $55 billion takeover bid five years ago.

Human hands working with documents at desk and signing contrac

Shire/Baxalta

by Carly Helfand

Flemming Ornskov, then the CEO of Shire, kicked off 2016’s J.P. Morgan Healthcare Conference with a celebration, pinning down a company he’d been chasing for months with buyout offers: Baxalta.

The top 15 biopharma M&A mistakes of the last decade

by Eric Sagonowsky

While many of the decade's M&A deals worked out for the buyers, others didn't deliver on their promises. Here, we feature 15 of those deals, including Bayer's Monsanto buy, Teva's purchase of Allergan's generics, AbbVie's Synageva pickup and many others.

Ex-Shire CEO Ornskov emerges as Galderma chief after Nestlé spin

by Angus Liu

Tuesday, October 8, 2019

Flemming Ornskov, Shire’s most recent CEO and who orchestrated the Baxalta takeover and later the selloff to Takeda, is now Galderma's CEO.

Takeda union accuses drugmaker of favoring Shire employees

by Angus Liu

Friday, August 2, 2019

Original Takeda employees alleged faced unfair changes in their roles and got different incentive plans during the integration.

Only AbbVie-Allergan megamerger looks like a winner: analyst

by Arlene Weintraub

Wednesday, July 24, 2019

SVB Leerink analysts are explaining why they like AbbVie's planned $63 billion acquisition of Allergan, and it all boils down to diversification.

Alnylam taps former Shire exec to replace departing CFO Soni

by Carly Helfand

Thursday, July 11, 2019

Ex-Shire CFO Jeff Poulton has landed at Alnylam. He'll replace current CFO Manmeet Soni, "arguably the best CFO in mid-cap biotech," one analyst said.

Takeda investors want execs to return pay if Shire lags

by Angus Liu

Wednesday, July 3, 2019

The majority of investors backed a proposal that would allow Takeda to claw back executive pay should the Shire deal not live up to expectations.

Takeda sets December deadline for U.S. employees' Boston move

by Kyle Blankenship

Thursday, June 27, 2019

After closing its $64 billion buyout of Shire, Takeda planned to move its headquarters—and up to 1,000 workers—to the Boston area.